Objective. To obtain an overview of rheumatic disorders occurring after hepatitis B vaccination.
Hepatitis B vaccine was initially recommended for adults cases of various diseases occurring after hepatitis B or children at high risk of hepatitis B virus (HBV ) vaccination, such as occlusion of the central retinal vein infection [1] . However, since vaccination programmes [12] , uveitis [13] , lichen ruber planus [14] , erythema had not been effective in reducing the incidence of HBV multiforme [15] , nephrotic syndrome [16 ] , acute cerebelinfection, immunization strategies including universal lar ataxia [17] , central nervous system demyelinization immunization of infants were developed [2] [3] [4] . Both [18] and transverse myelitis [19] . A few cases of rheumplasma-derived and recombinant hepatitis B vaccines atological manifestations have been reported [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . are safe to administer to adults and children. The sideHowever, it is difficult to know whether there is a effects are usually minor, including headache, injection coincidental or a causal relationship between immunizasite pain, tiredness, fever, arthralgia [5] [6] [7] [8] [9] [10] [11] . These reaction and the observed manifestations. This paper reports tions usually resolve within 24-48 h. Serious adverse our experience of a larger series of 22 patients. The aim effects are rare [5] [6] [7] [8] [9] [10] [11] . However, medical and public of our work was not to assess whether hepatitis B interest in the safety of hepatitis B vaccination was immunization is associated or not with an incidence of recently heightened by medical journals and media rheumatic disorders higher than normal, but to obtain reports of adverse effects. Some authors have described an overview of articular problems that might occur after such a vaccination. Some aspects of a single case have previously been published as a case report [33] .
Systemic lupus erythematosus (SLE)

Methods
Two women developed exacerbation of SLE. The first In 1997, a questionnaire about rheumatic complaints patient presented with an arthritis of the right ankle following hepatitis B vaccination was sent to the occurring 1 week after immunization. The blood cell rheumatology departments of the hospitals in Besançon, count showed moderate neutropenia (1800) and lymBourg en Bresse, Chalon sur Saone, Dijon, Grenoble, phopenia (1300). The tests for antinuclear antibodies Pierre Bénite, Reims, Saint Etienne and Strasbourg (ANA) on Hep-2 cells (1:640) and for anti-SSA antibod-(France). Criteria for entry were any rheumatic comies were positive. She had no anti-double-stranded (ds) plaints of 1 week duration or more, occurrence of the DNA. The second patient presented with thrombocytocomplaints during the 2 months following hepatitis B penic purpura occurring 1 month after the third injection vaccination, no previously diagnosed rheumatic disease of the vaccine series. The tests for ANA (1:1280), antiand no other explanation for the occurrence of comdsDNA, anticardiolipin and anti-SSA antibodies were plaints. The participating hospitals were given no indicapositive. In both patients, the affection was probably tion as to the time period of interest. The clinical and present prior to the vaccination: the first had a 4 yr laboratory data from all patients were collected and history of photosensitivity; the second had a 2 yr history analysed retrospectively.
of migratory polyarthralgia.
'Post-vaccinal' arthritis
Results
Five women developed 'post-vaccinal' arthritis. The Twenty-two patients were included. There were three distribution of arthritis was heterogeneous: symmetrical males and 19 females, mean age 31.5 ± 12.4 (..) yr polyarthritis in the first patient, right and left metacarpo-(range 15-53 yr). All patients received recombinant hepphalangeal joints in the second patient, monoarthritis atitis B vaccine between 1992 and 1997. Two were given of the knee in the third patient, and asymmetrical several vaccines (hepatitis A and hepatitis B for one migratory oligoarthritis predominating in the lower limb patient; hepatitis B, rubeola and typhoid for the other).
in the last two patients. In three cases, a further vaccine Among the 22 cases, eight developed symptoms after injection was performed, resulting in all cases in the first vaccine dose, five after the second dose, three worsening of the complaints. The patients were all after the third dose (1 month between two injections) treated with non-steroidal anti-inflammatory drugs and six after a booster injection. The last six patients (NSAIDs). For two of them, the complaints regressed had not complained of adverse events after the previous completely. In a third patient, the complaints regressed injections. For 10 patients, the next hepatitis B vaccine under NSAIDs, but she still complained of moderate inoculation was performed despite the complaints. The arthralgia after 3 months of therapy. For the two other complaints worsened in eight cases and were not modipatients, classical NSAIDs proved ineffective and were fied in one (the effects of the new injection are unknown discontinued. For the first, treatment with prednisone for the last patient). The time interval between the (1 mg/kg/day) resulted in a dramatic improvement. vaccination and the occurrence of complaints was ∏ 1 During the next 6 months, the dose of prednisone was week for nine patients, between 1 week and 1 month progressively diminished. At this time, the treatment for 10 patients, and 2 months for three patients. Owing was discontinued. No recurrent attack occurred during to the retrospective analysis, the laboratory investithe follow-up (3 yr). For the last patient, treatment with gations for differential diagnosis were performed accordphenylbutazone resulted in some improvement, but the ing to the complaints, and were not the same for all arthritis persisted for 5 months. At the present time, patients. In particular, extensive serological tests were 15 months after initiation of phenylbutazone, she not performed in all cases. A summary of cases is given complains of arthralgia, but the arthritis has regressed. in Table 1 .
Consequently, a characteristic outcome in all these patients was that the arthritis regressed, although some Rheumatoid arthritis (RA) were left with arthralgia.
Six women developed an inflammatory polyarthritis
Arthralgia, myalgia satisfying the 1987 ARA criteria for the diagnosis of RA. They had received immunization 1, 2, 3, 10, 18 and Four patients suffered from polyarthralgia and myalgia, 20 days, respectively, prior to symptom onset. All and three of them from fatigue. The complaints persisted received another injection. The symptoms worsened in for 2 months in the first patient and 1 yr in the second four cases, and were not modified in one (the effects of one, and then disappeared. In the third patient, the the next injection were unknown for the last patient).
complaints have persisted for 3 months, but are now The follow-up is now 6, 5, 3, and 2 yr, and 20 and 6
improving. In the last patient, the complaints persisted months, respectively. The affection is still persisting.
for 13 months. The patient was then lost to follow-up. During the follow-up, all patients were treated with Suspected or proven vasculitis at least one disease-modifying anti-rheumatic drug (DMARD), including methotrexate for four. Joint eroOne patient developed a biopsy-proven vasculitis, and two others developed manifestations suggesting vasculsions occurred in three out of the five patients followed up for >1 yr.
itis, but no biopsy was performed for confirmation. The clinical manifestations were: polyarthritis, pain in the influenza vaccine and miscellaneous) are clinically indistinguishable from other patients with inflammatory cervical column, myalgia, skin rash with vesicle ( leucocytoclastic vasculitis on skin biopsy), low-grade fever polyarthritis. A few cases of onset or reactivation of SLE after (38°C ) for one patient; polyarthritis, abdominal pain, urticaria, low-grade fever (37.8°C ) for another patient; vaccination against hepatitis B have been described [25, 35, 36 ] . The onset of symptoms occurred within pain in the cervical column and mental nerve neuropathy, followed by low-back pain, arthralgia and 5 days-1 month after the immunization. Two patients had a lupus nephritis (associated in one with fever and paraesthesiae of the lower limbs for the last patient. The complaints regressed rapidly under NSAIDs (two arthralgia), one patient had pericarditis, one had thrombocytopenic purpura. For all patients, the tests patients) or spontaneously (one patient).
for ANA were positive. The evolution was favourable Miscellaneous in all after therapy using corticosteroids and, in one, on A 43-yr-old man developed fever (38°C ), erythema cyclophosphamide. nodosum and oligoarthritis of the inferior limbs. He Several cases of reactive arthritis following hepatitis was treated with NSAIDs. The complaints regressed B vaccination have been reported [20, 22, 26, 32] . Some within 1 month.
reports of Reiter's syndrome [23] and psoriatic arthro-A 53-yr-old man complained of migratory inflampathy [27] can probably or possibly be added to these matory polyarthralgia, talalgia, and sensation of dry cases. The symptoms were often controlled with eyes and mouth. He was referred to an ophthalmologist, NSAIDs, but sulphasalazine was sometimes needed. The who demonstrated sicca syndrome (Rose Bengal test), complaints frequently regressed after a few months. and was successfully treated with NSAIDs. Four months
We observed four patients with myalgia and polylater, he was well, with persistence of moderate arthralarthralgia, and, in three of them, fatigue following gia. In particular, the sensation of dry eyes and mouth hepatitis B vaccination. These manifestations can be had regressed. Unfortunately, he was not referred to an connected to the chronic fatigue syndrome. A few years ophthalmologist at this time, and was then lost to ago, an independent working group agreed that there follow-up.
was no evidence of a cause-effect relationship between hepatitis B vaccine and chronic fatigue syndrome [37] . However, the number of patients followed up may have Discussion been too small to detect a slight increase in the relative Rheumatic disorders described after hepatitis B risk. immunization Various other conditions following hepatitis B vaccination have been described. They include erythema Some observations suggest that hepatitis B vaccine might be followed by various rheumatic conditions. These nodosum and polyarthritis [21] , erythema nodosum with arthralgia and Takayasu's arteritis [38] , vasculitis conditions can be put together in two groups: transient conditions, such as vasculitis, post-vaccinal arthritis, [39] [40] [41] , polyarthritis associated with hypercalcaemia and lytic bone lesions [29] . In most cases, the complaints erythema nodosum; and onset or relapse of rheumatic (RA, lupus erythematosus, spondyloarthropathies, were treated with NSAIDs or steroids, persisted for a few days, weeks or months, then regressed without etc.) or non-rheumatic (multiple sclerosis, etc.) chronic diseases.
recurrence. In our series, we observed one case of erythema nodosum with oligoarthritis and one case of At least 20 cases of patients satisfying the 1987 ARA criteria for the diagnosis of RA have been described vasculitis confirmed by skin biopsy. Two other patients developed manifestations suggesting vasculitis, but (including ours) [24, 26, 28, 30, 31] . The patients were five men and 15 women, aged from 20 to 58 yr. The biopsies were not performed to confirm it. In all cases, the manifestations regressed spontaneously, or under onset of symptoms occurred within 1-30 days following the vaccination. Despite the arthritis, nine patients NSAIDs or steroids, and did not recur. Several pathogenetic models can be put forward to received a new injection of vaccine. The arthritis worsened in six and was unchanged in one. The effects explain rheumatic disorders following hepatitis B vaccination. Transient conditions might be due to deposof the new injection are unknown in the two others. The tests for rheumatoid factor (RF ) were positive in ition within the synovium of circulating immune complexes containing viral antigen and anti-HBs anti-10 out of 13 patients. HLA testing showed the presence of DR1 and/or DR4 antigen in 14 out of 16 patients.
bodies, such as observed in some hepatitis B infections, or they might be due to hypersensitivity to some comDuring the evolution, at least 12 patients needed DMARDs, and joint erosions or periarticular osteoponents of the vaccine, such as thimesoral [42, 43] or yeast proteins [44] . Onset of chronic inflammatory or porosis occurred in 10 (data not known for some patients). These data suggest that there is apparently no autoimmune diseases might be due to molecular mimicry or to post-immunization conditions indistinguishable difference between cases of RA following hepatitis B vaccination and other RA. This is in accordance with from individualized diseases. The diversity of the observed diseases is not in favour of these hypotheses. results from Harrison et al. [34] , who suggested that patients who develop inflammatory polyarthritis, especi-A more attractive hypothesis is that hepatitis B immunization might trigger the onset or the relapse of the ally RA, after various immunizations (tetanus toxoid, diseases in individuals with underlying genetic and Consequently, we do not know what percentage of patients seen in our departments during the period immunological susceptibility [34] .
covered by the study developed symptoms following Coincidental or causal relationship?
immunization. Moreover, we do not know how many patients developing musculoskeletal symptoms following However, it is difficult to know whether there is a coincidental or a causal relationship between immunizahepatitis B immunization were treated by office-based rheumatologists or general practitioners during the time tion and the observed rheumatic manifestations. Our work was an observational retrospective study, and was period covered by the study. Consequently, at this time, there is a discrepancy not performed to respond to this question. Since the investigations performed for differential diagnosis were between the negative results of epidemiological studies and the description of suggestive cases, including ours. not the same for all patients, we cannot exclude some misdiagnosis. Particularly in some patients (those who
Further epidemiological studies including a sufficient number of subjects to detect a slight increase in the underwent hepatitis B and other immunizations before the occurrence of complaints, those with a time interval relative risk are needed to establish whether hepatitis B vaccination is associated or not with an incidence of of >1 month between the vaccination and the occurrence of complaints), the imputation may be considered rheumatic disorders higher than normal. On the other hand, the presumed risk for adverse as more doubtful. Moreover, our large series could be due to a recent French national campaign to encourage events must be weighed against the expected risk for HBV-related liver disease [6 ] . Since the relative risk of adolescents and young adults to receive hepatitis B vaccine. Following this campaign, a great number of occurrence of rheumatic complaints following hepatitis B vaccination is not or is slightly increased compared subjects (including middle-aged subjects) received the vaccine and, at this time, >20 million French people to the general population, the morbidity and mortality that can be prevented by immunization against hepatitis have been vaccinated (but it is difficult to know exactly the total number of people immunized between 1992 B outweigh by far the risk of possible adverse events [42] . Consequently, in our opinion, the possible rheumand 1997). A number of these subjects would have developed rheumatic disorders if not vaccinated. Our atic adverse effects do not put into question universal immunization. However, questions are raised about national reporting system did not show any increase in the incidence of autoimmune disorders following hepatitis B vaccine recommendation in some patients, especially those with chronic inflammatory or autohepatitis B immunization. This result is in favour of a coincidental relationship.
immune diseases, and those with previously suspected adverse effects related to hepatitis B immunization. However, several arguments are in favour of a causal relationship. For a majority of patients, the temporal Studies are needed to respond to these questions.
In conclusion, hepatitis B vaccine might be followed association was suggestive. The manifestations worsened in most of the patients who were given a further by various rheumatic conditions and might trigger the onset of underlying inflammatory or autoimmune injection. In some patients, the complaints regressed after a few weeks or months, and did not recur during rheumatic diseases. However, a causal relationship between hepatitis B vaccination and the observed rheumthe follow-up. In most patients, the explorations and the follow-up did not show any other plausible cause atic manifestations cannot be easily established. Further epidemiological studies are needed to establish whether for the complaints. Moreover, since patients with rheumatic disorders were not systematically questioned about hepatitis B vaccination is associated or not with an incidence of rheumatic disorders higher than normal. prior immunization in the past years, and since the national reporting system of drug adverse effects is based not on obligatory but on voluntary notifications, the
